Monte Rosa Therapeutics, Inc. Common Stock

Monte Rosa Therapeutics presented preclinical data on MRT-8102, a molecular glue degrader targeting NEK7, which shows potential in treating cardiovascular and cardiometabolic diseases by modulating the NLRP3 inflammasome pathway.

Monte Rosa Therapeutics announced a collaboration with Novartis to develop novel AI-powered degraders for immune-mediated diseases, receiving $120 million upfront and potential milestone payments up to $5.7 billion.

Monte Rosa Therapeutics (GLUE) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Analysts have high hopes for these three innovation companies in 2024.

Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week